RCT DUPLICATE
  • Home
  • Core Team
  • Projects
    • FDA Demonstration Project
    • FDA Prediction Project
    • NHLBI Grant
    • Other Prospective Projects
  • Publications
  • Project Updates
  • Contact Us
  • Expert Advisory Panel
  • Collaborators

Other Prospective Replications

Picture
CAROLINA
This trial is in progress. We will post the relevant publications upon trial completion. Below are protocol or baseline characteristic papers for the trial.
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA).
Marx N, et al. Diab Vasc Dis Res 2015; 12(3): 164-174
read article

DECLARE TIMI 58
This trial is in progress. We will post the relevant publications upon trial completion. Below are protocol or baseline characteristic papers for the trial.
DECLARE-TIMI 58: Participants' baseline characteristics.
Raz I, et al. Diabetes Obes Metab 2018; 20(5): 1102-1110
read article

ENTRACTE Trial
Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: Results of a randomized, parallel-group, multicenter, non-inferiority, phase 4 clinical trial [abstract].
Giles JT, et al. Arthritis Rheumatol 2016; 68 (suppl 10)
Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis - a multi-database cohort study.
Kim SC, et al. Arthritis Rheumatol 2017; 69(6): 1154-64
read article
read article

CANVAS
Cangliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, et al. New Engl J Med 2017; 377: 644-57
Cardiovascular safety of canagliflozin versus other non-gliflozin antidiabetic agents: A population-based cohort study.
Patorno E, et al. BMJ 2018; 360: k119
read article
read article
Powered by Create your own unique website with customizable templates.
  • Home
  • Core Team
  • Projects
    • FDA Demonstration Project
    • FDA Prediction Project
    • NHLBI Grant
    • Other Prospective Projects
  • Publications
  • Project Updates
  • Contact Us
  • Expert Advisory Panel
  • Collaborators